Search

Soonmyung Paik

from Pittsburgh, PA
Age ~67
Get Report
Also known as:
Soon Myung Dr Paik, Soon Myung Paik, Soon Myoung Paik, Soon-Myung Paik, Soon Myung Lk, Soon Myung Palk, G Paik, Myung Paik G, Soom Piak
Phone and address:
100 Anderson St, Pittsburgh, PA 15212
(412) 323-9498
Related to:
Hwan Park Jeong, 56Soon-Myung Paik, 67
Connected to:
Amy J Paik, 41Angie E Paik, 65Augustine W Paik, 70Clara K Paik, 54Ingle K Paik, 74Jangmi Paik, 37June H Paik, 67Justin Paik, 36Nathanael L Paik, 41Rachel E Paik, 38

Soonmyung Paik Phones & Addresses

  • 100 Anderson St, Pittsburgh, PA 15212 (412) 323-9498
  • 210 Timber Ridge Rd, Pittsburgh, PA 15238 (412) 406-7548
  • Rockville, MD

Professional Records

Medicine Doctors

Soonmyung Paik Photo 1

Soonmyung Paik, Pittsburgh PA

View page
Specialties:
Pathology
Anatomic Pathology
Work:
Nsabp
4 Allegheny Ctr, Pittsburgh, PA 15212
Education:
Yonsei University (1981)

Publications

Us Patents

Molecular Indicators Of Breast Cancer Prognosis And Prediction Of Treatment Response

View page
US Patent:
7622251, Nov 24, 2009
Filed:
Nov 4, 2005
Appl. No.:
11/267807
Inventors:
Joffre B. Baker - Montara CA, US
John L. Bryant - Allison Park PA, US
Soonmyung Paik - Pittsburgh PA, US
Steven Shak - Hillsborough CA, US
Assignee:
Genomic Health, Inc. - Redwood City CA
NSABP Foundation, Inc. - Pittsburgh PA
International Classification:
C12Q 1/68
US Classification:
435 6
Abstract:
The present invention relates to quantitative molecular indicators that can guide clinical decisions in breast cancer, such as estrogen receptor (ESR1)-positive, lymph node-negative breast cancer. In particular, the invention concerns certain genes, the varied expression of which indicates the likelihood of recurrence of surgically resected breast cancer in patients who are not treated with a therapeutic agent in the adjuvant setting. In addition, the invention concerns the use of quantitative measurement of the expression of certain genes, including the ESR1 gene, that measure as a continuous variable, to determine (a) the likelihood of a beneficial response to the anti-estrogen therapeutic agent, such as tamoxifen; and (b) the potential magnitude of beneficial response to chemotherapy.

Gene Expression Markers For Colorectal Cancer Prognosis

View page
US Patent:
7695913, Apr 13, 2010
Filed:
Jan 11, 2007
Appl. No.:
11/653102
Inventors:
Wayne Cowens - Tiburon CA, US
Joffre B. Baker - Montara CA, US
Kim Clark - Sunnyvale CA, US
James Hackett - San Jose CA, US
Drew Watson - Los Altos CA, US
Soonmyung Paik - Pittsburgh PA, US
Assignee:
Genomic Health, Inc. - Redwood City CA
NSABP Foundation, Inc. - Pittsburgh PA
International Classification:
C12Q 1/68
US Classification:
435 6
Abstract:
A method of predicting clinical outcome in a subject diagnosed with colorectal cancer comprising determining evidence of the expression of one or more predictive RNA transcripts or their expression products in a biological sample of cancer cells obtained from the subject.

Prediction Of Likelihood Of Cancer Recurrence

View page
US Patent:
7723033, May 25, 2010
Filed:
Jan 31, 2006
Appl. No.:
11/345611
Inventors:
Joffre B. Baker - Montara CA, US
John L. Bryant - Pittsburgh PA, US
Soonmyung Paik - Pittsburgh PA, US
Steven Shak - Hillsborough CA, US
Assignee:
Genomic Health, Inc. - Redwood City CA
NSABP Foundation, Inc. - Pittsburgh PA
International Classification:
C12Q 1/68
C12P 19/34
C07H 21/04
US Classification:
435 6, 435 912, 536 235, 536 2431, 536 2433
Abstract:
The present invention provides gene sets, the expression of which is important in the diagnosis and/or prognosis of cancer, in particular of breast cancer.

Predicting Response To Chemotherapy Using Gene Expression Markers

View page
US Patent:
7930104, Apr 19, 2011
Filed:
Nov 4, 2005
Appl. No.:
11/267769
Inventors:
Joffre B. Baker - Montara CA, US
John L. Bryant - Allison Park PA, US
Soonmyung Paik - Pittsburgh PA, US
Steven Shak - Hillsborough CA, US
Assignee:
Genomic Health, Inc. - Redwood City CA
NSABP Foundation, Inc. - Pittsburgh PA
International Classification:
C12Q 1/68
G01N 33/48
G06G 7/58
US Classification:
702 19, 435 6, 702 20, 703 11
Abstract:
The present invention provides gene expression information useful for predicting whether a cancer patient is likely to have a beneficial response to treatment with chemotherapy, comprising measuring, in a biological sample comprising a breast tumor sample obtained from the patient, the expression levels of gene subsets to obtain a risk score associated with a likelihood of a beneficial response to chemotherapy, wherein the score comprises at least one of the following variables: (i) Recurrence Score, (ii) ESRI Group Score; (iii) Invasion Group Score; (iv) Proliferation Group Score; and (v) the expression level of the RNA transcript of at least one of MYBL and SCUBE, or the corresponding expression product. The invention further comprises a molecular assay-based algorithm to calculate the likelihood that the patient will have a beneficial response to chemotherapy based on the risk score.

Expression Profile Algorithm And Test For Cancer Prognosis

View page
US Patent:
7939261, May 10, 2011
Filed:
Mar 18, 2009
Appl. No.:
12/406831
Inventors:
Joffre B. Baker - Montara CA, US
John L. Bryant - Allison Park PA, US
Soonmyung Paik - Pittsburgh PA, US
Steven Shak - Hillsborough CA, US
Assignee:
Genomic Health, Inc. - Redwood City CA
NSABP Foundation, Inc. - Pittsburgh PA
International Classification:
C12Q 1/68
G06F 19/00
US Classification:
435 6, 702 20
Abstract:
The present invention provides a noninvasive, quantitative test for prognosis determination in cancer patients. The test relies on measurements of the tumor levels of certain messenger RNAs (mRNAs). These mRNA levels are inserted into a polynomial formula (algorithm) that yields a numerical recurrence score, which indicates recurrence risk.

Gene Expression Markers For Colorectal Cancer Prognosis

View page
US Patent:
8026060, Sep 27, 2011
Filed:
Oct 25, 2010
Appl. No.:
12/911551
Inventors:
Drew Watson - Los Altos CA, US
Soonmyung Paik - Pittsburgh PA, US
Wayne Cowens - Tiburon CA, US
Joffre B. Baker - Montara CA, US
Kim Clark - Sunnyvale CA, US
James Hackett - San Jose CA, US
Assignee:
Genomic Health, Inc. - Redwood City CA
NSABP Foundation, Inc. - Pittsburgh PA
International Classification:
C12Q 1/68
US Classification:
435 6, 435 912
Abstract:
A method of predicting clinical outcome in a subject diagnosed with colorectal cancer comprising determining evidence of the expression of one or more predictive RNA transcripts or their expression products in a biological sample of cancer cells obtained from the subject.

Gene Expression Markers For Colorectal Cancer Prognosis

View page
US Patent:
8029995, Oct 4, 2011
Filed:
Oct 25, 2010
Appl. No.:
12/911532
Inventors:
Drew Watson - Los Altos CA, US
Soonmyung Paik - Pittsburgh PA, US
Wayne Cowens - Tiburon CA, US
Joffre B. Baker - Montara CA, US
Kim Clark - Sunnyvale CA, US
James Hackett - San Jose CA, US
Assignee:
Genomic Health, Inc. - Redwood City CA
NSABP Foundation, Inc. - Pittsburgh PA
International Classification:
C12Q 1/68
US Classification:
435 6, 435 912
Abstract:
A method of predicting clinical outcome in a subject diagnosed with colorectal cancer comprising determining evidence of the expression of one or more predictive RNA transcripts or their expression products in a biological sample of cancer cells obtained from the subject.

Gene Expression Markers For Prediction Of Patient Response To Chemotherapy

View page
US Patent:
8067178, Nov 29, 2011
Filed:
Mar 13, 2009
Appl. No.:
12/404268
Inventors:
Joffre B. Baker - Montara CA, US
Wayne Cowens - Tiburon CA, US
Kim Langone - Sunnyvale CA, US
James Hackett - San Jose CA, US
Drew Watson - Los Altos CA, US
Soonmyung Paik - Pittsburgh PA, US
Assignee:
Genomic Health, Inc. - Redwood City CA
NSABP Foundation, Inc. - Pittsburgh PA
International Classification:
C12Q 1/68
G01N 33/53
US Classification:
435 614, 435 612, 435 71
Abstract:
The present invention relates to gene sets useful in assessing prognosis and/or predicting the response of cancer, e. g. colorectal cancer to chemotherapy. In addition, the invention relates to a clinically validated cancer test, e. g. colorectal test, for assessment of prognosis and/or prediction of patient response to chemotherapy, using expression analysis. The present invention accommodates the use of archived paraffin embedded biopsy material for assay of all markers in the relevant gene sets and therefore is compatible with the most widely available type of biopsy material.
Control profile
Soonmyung Paik from Pittsburgh, PA, age ~67 Get Report